24.5 C
New York
Saturday, September 18, 2021
spot_img

Sitting on a Cash Pile 12.0? BioTech Favored Over Legacy Pharma

#cash #bullish #buy

$BCRX

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) brokout on 10 November at 4.08 and confirmed on 11 March at 11.98. Thus garnering an LTN Cash Pile Buy rating with a 1yr price target at 16+/share

The stock is currently trading at 11.98 within its 52 wk trading range of 1.58 – 12.90

The consensus 1 yr price objective is 13.78. Our price target is 16/share.

The Key support is at 11.17 and the resistance is light at 12.72. the majority of our Key technical indicators are Very Bullish in here.

BioCryst Pharmaceuticals, Inc., a biotech company, discovers oral and small-molecule medicines.

The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.

The company has collaborations and in-license relationships with US Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.

BioCryst Pharmaceuticals, Inc. was founded in Y 1986 and is HQ’d in Durham, North Carolina.

Have a healthy day, Keep the Faith!

Paul Ebeling
Paul A. Ebeling, a polymath, excels, in diverse fields of knowledge Including Pattern Recognition Analysis in Equities, Commodities and Foreign Exchange, and he is the author of "The Red Roadmaster's Technical Report on the US Major Market Indices, a highly regarded, weekly financial market commentary. He is a philosopher, issuing insights on a wide range of subjects to over a million cohorts. An international audience of opinion makers, business leaders, and global organizations recognize Ebeling as an expert.   

Related Articles

Stay Connected

15,334FansLike
43,300FollowersFollow
2,855SubscribersSubscribe
- Advertisement -spot_img

Latest Articles